ClearPoint NeuroCLPT
About: ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.
Employees: 107
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1,361% more call options, than puts
Call options by funds: $7.09M | Put options by funds: $485K
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
53% more capital invested
Capital invested by funds: $76.6M [Q3] → $117M (+$40.3M) [Q4]
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
13% more funds holding
Funds holding: 78 [Q3] → 88 (+10) [Q4]
2.8% more ownership
Funds ownership: 24.76% [Q3] → 27.56% (+2.8%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
B. Riley Securities Neil Chatterji 100% 1-year accuracy 2 / 2 met price target | 20%upside $20 | Buy Maintained | 28 Jan 2025 |
Lake Street Frank Takkinen 55% 1-year accuracy 11 / 20 met price target | 79%upside $30 | Buy Maintained | 21 Jan 2025 |
Financial journalist opinion
Based on 4 articles about CLPT published over the past 30 days









